about
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this imm...
Read More
42.48
-0.66
(-1.53%)
2.2M
XNAS Volume
XNAS 18 Sep, 2026 5:30 PM (EDT)
Low Financial Strength
Affordable Valuation
Technically Neutral
Risky Value
These stocks have weak financials and average momentum. They may be affordable, but investors should exercise caution
View Similar
Embed DVM
Sanofi (ADR) Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..